LENZ Therapeutics (LENZ) Competitors $42.03 +2.00 (+5.00%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$41.40 -0.63 (-1.50%) As of 09/26/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. PTCT, KRYS, ACLX, ARWR, PCVX, ACAD, PTGX, ADMA, MIRM, and ZLABShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arcellx (ACLX), Arrowhead Pharmaceuticals (ARWR), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Protagonist Therapeutics (PTGX), ADMA Biologics (ADMA), Mirum Pharmaceuticals (MIRM), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Its Competitors PTC Therapeutics Krystal Biotech Arcellx Arrowhead Pharmaceuticals Vaxcyte ACADIA Pharmaceuticals Protagonist Therapeutics ADMA Biologics Mirum Pharmaceuticals Zai Lab PTC Therapeutics (NASDAQ:PTCT) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Which has more volatility and risk, PTCT or LENZ? PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Which has higher valuation & earnings, PTCT or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.81-$363.30M$6.978.46LENZ Therapeutics$5M239.76-$49.77M-$1.90-22.12 Do analysts recommend PTCT or LENZ? PTC Therapeutics presently has a consensus price target of $69.00, suggesting a potential upside of 16.97%. LENZ Therapeutics has a consensus price target of $49.60, suggesting a potential upside of 18.01%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in PTCT or LENZ? 54.3% of LENZ Therapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is PTCT or LENZ more profitable? PTC Therapeutics has a net margin of 35.65% compared to LENZ Therapeutics' net margin of 0.00%. LENZ Therapeutics' return on equity of -25.63% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% LENZ Therapeutics N/A -25.63%-24.43% Does the media refer more to PTCT or LENZ? In the previous week, LENZ Therapeutics had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 3 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.44 beat LENZ Therapeutics' score of 1.07 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPTC Therapeutics and LENZ Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$3.07B$5.63B$10.31BDividend YieldN/A2.43%5.77%4.65%P/E Ratio-22.1221.1975.7526.15Price / Sales239.76260.70479.95100.63Price / CashN/A44.6837.1160.83Price / Book5.669.7412.416.36Net Income-$49.77M-$52.93M$3.29B$270.97M7 Day Performance-0.57%3.76%1.23%0.33%1 Month Performance12.47%7.37%3.39%6.05%1 Year Performance74.83%18.23%63.27%27.33% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.2336 of 5 stars$42.03+5.0%$49.60+18.0%+88.9%$1.14B$5M-22.12110PTCTPTC Therapeutics3.9218 of 5 stars$60.85+0.6%$69.00+13.4%+56.6%$4.80B$806.78M8.731,410Positive NewsKRYSKrystal Biotech4.9453 of 5 stars$165.42+1.1%$209.00+26.3%-5.9%$4.73B$290.52M33.62210Positive NewsACLXArcellx2.0634 of 5 stars$78.22+0.5%$114.31+46.1%-5.2%$4.32B$107.94M-22.8780Insider TradeARWRArrowhead Pharmaceuticals4.1349 of 5 stars$32.05+4.4%$43.14+34.6%+67.2%$4.24B$3.55M-25.04400PCVXVaxcyte1.7607 of 5 stars$33.47+5.4%$106.25+217.4%-69.5%$4.12BN/A-8.14160ACADACADIA Pharmaceuticals4.318 of 5 stars$24.53+0.5%$29.65+20.9%+36.0%$4.12B$957.80M18.44510Trending NewsAnalyst ForecastOptions VolumePTGXProtagonist Therapeutics1.4553 of 5 stars$64.51+3.7%$68.08+5.5%+50.1%$3.87B$434.43M92.16120Insider TradeADMAADMA Biologics3.2521 of 5 stars$16.03+0.8%$27.67+72.6%-19.7%$3.80B$426.45M18.64530Positive NewsMIRMMirum Pharmaceuticals3.4077 of 5 stars$73.93-0.6%$74.44+0.7%+88.0%$3.74B$336.89M-61.10140News CoverageAnalyst ForecastZLABZai Lab2.8858 of 5 stars$33.15+1.5%$56.35+70.0%+39.9%$3.65B$398.99M-16.251,869 Related Companies and Tools Related Companies PTCT Competitors KRYS Competitors ACLX Competitors ARWR Competitors PCVX Competitors ACAD Competitors PTGX Competitors ADMA Competitors MIRM Competitors ZLAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 9/27/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LENZ Stock Alerts